VR Advisory Services’s Aspire Biopharma Warrant ASBPW Stock Holding History

VR Advisory Services’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-99,692	Closed	-$1.66K	–	46
2026 Q1	$1.66K	Hold	99,692	–	–	﹤0.01%	40
2025 Q4	$1.65K	Hold	99,692	–	–	﹤0.01%	37
2025 Q3	$2.98K	Hold	99,692	–	–	﹤0.01%	35
2025 Q2	$4.45K	Buy	+99,692	New	+$4.92K	﹤0.01%	32

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

VR Advisory Services's ASBPW Position: Q2 2026 in Review

VR Advisory Services sold out of Aspire Biopharma Warrant (ASBPW) in Q2 2026, closing a stake of 99,692 shares — an estimated $1.66K sold.

VR Advisory Services first reported a position in ASBPW in Q2 2025 and held it in 4 quarters. The position peaked at $4.45K in Q2 2025. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

VR Advisory Services reported no remaining Aspire Biopharma Warrant position as of Q2 2026 after selling out during the quarter.
VR Advisory Services sold 99,692 Aspire Biopharma Warrant shares in Q2 2026, an estimated $1.66K.
VR Advisory Services first reported a position in Aspire Biopharma Warrant in Q2 2025 and held it in 4 quarters.
VR Advisory Services's Aspire Biopharma Warrant position peaked at $4.45K in Q2 2025.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on VR Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.